Catalyst Wire Dossier Catalyst Wire Dossier

Xarelto (rivaroxaban)

rivaroxaban · Bayer/Janssen Pharmaceuticals
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Xarelto (rivaroxaban), covering 2022-03-28 to 2025-01-16. Get the full timeline:

Most recent: Clinical Trial Update: Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)

See pricing